Drug
non-nucleoside reverse transcriptase inhibitors
Total Trials
2
Max Phase
-
Type
DRUG
Molecule
-
Registry-listed formulations
This catalogue entry has no confirmed scientific concept.
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
0 source entries across 0 studies. This list may not include all unresolved or historical entries.
Success Metrics
Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(100%)
Phase Distribution
Phase 4
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Terminated(2)
Detailed Status
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (100.0%)
Trials by Status
terminated2100%
Recent Activity
0 active trials
Showing 2 of 2
terminatedphase_4
Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
NCT00122655
terminatedphase_4
Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
NCT00122668
Clinical Trials (2)
Showing 2 of 2 trials
NCT00122655Phase 4
Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
NCT00122668Phase 4
Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
All 2 trials loaded
Drug Details
- Intervention Type
- Drug
- Total Trials
- 2